ID   TGFR1_HUMAN             Reviewed;         503 AA.
AC   P36897; Q6IR47; Q706C0; Q706C1;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1994, sequence version 1.
DT   10-MAY-2017, entry version 201.
DE   RecName: Full=TGF-beta receptor type-1;
DE            Short=TGFR-1;
DE            EC=2.7.11.30;
DE   AltName: Full=Activin A receptor type II-like protein kinase of 53kD;
DE   AltName: Full=Activin receptor-like kinase 5;
DE            Short=ALK-5;
DE            Short=ALK5;
DE   AltName: Full=Serine/threonine-protein kinase receptor R4;
DE            Short=SKR4;
DE   AltName: Full=TGF-beta type I receptor;
DE   AltName: Full=Transforming growth factor-beta receptor type I;
DE            Short=TGF-beta receptor type I;
DE            Short=TbetaR-I;
DE   Flags: Precursor;
GN   Name=TGFBR1; Synonyms=ALK5, SKR4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=8242743; DOI=10.1016/0092-8674(93)90489-D;
RA   Franzen P., ten Dijke P., Ichijo H., Yamashita H., Schulz P.,
RA   Heldin C.-H., Miyazono K.;
RT   "Cloning of a TGF beta type I receptor that forms a heteromeric
RT   complex with the TGF beta type II receptor.";
RL   Cell 75:681-692(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=9417915; DOI=10.1006/geno.1997.5023;
RA   Vellucci V.F., Reiss M.;
RT   "Cloning and genomic organization of the human transforming growth
RT   factor-beta type I receptor gene.";
RL   Genomics 46:278-283(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Lynch M.A., Song H., DeGroff V.L., Alam K.Y., Adams E.M.,
RA   Weghorst C.M.;
RT   "The genomic structure of the gene encoding the human transforming
RT   growth factor beta type I receptor.";
RL   Submitted (NOV-1997) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NIEHS SNPs program;
RL   Submitted (DEC-2003) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E.,
RA   Howe K.L., Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Ashwell R.I.S.,
RA   Babbage A.K., Babbage S., Bagguley C.L., Bailey J., Banerjee R.,
RA   Barker D.J., Barlow K.F., Bates K., Beasley H., Beasley O., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burford D., Burrill W.,
RA   Burton J., Carder C., Carter N.P., Chapman J.C., Chen Y., Clarke G.,
RA   Clark S.Y., Clee C.M., Clegg S., Collier R.E., Corby N., Crosier M.,
RA   Cummings A.T., Davies J., Dhami P., Dunn M., Dutta I., Dyer L.W.,
RA   Earthrowl M.E., Faulkner L., Fleming C.J., Frankish A.,
RA   Frankland J.A., French L., Fricker D.G., Garner P., Garnett J.,
RA   Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M.,
RA   Lovell J., Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S.,
RA   McLay K.E., McMurray A., Milne S., Nickerson T., Nisbett J.,
RA   Nordsiek G., Pearce A.V., Peck A.I., Porter K.M., Pandian R.,
RA   Pelan S., Phillimore B., Povey S., Ramsey Y., Rand V., Scharfe M.,
RA   Sehra H.K., Shownkeen R., Sims S.K., Skuce C.D., Smith M.,
RA   Steward C.A., Swarbreck D., Sycamore N., Tester J., Thorpe A.,
RA   Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Williams S.A., Wilming L., Wray P.W.,
RA   Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S.,
RA   Rogers J., Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   PROTEIN SEQUENCE OF 34-40, SIGNAL SEQUENCE CLEAVAGE SITE,
RP   GLYCOSYLATION, CHARACTERIZATION OF VARIANT TGFBR1*6A ALA-24--26-ALA
RP   DEL, AND VARIANT TGFBR1*10A ALA-26 INS.
RX   PubMed=9661882;
RA   Pasche B., Luo Y., Rao P.H., Nimer S.D., Dmitrovsky E., Caron P.,
RA   Luzzatto L., Offit K., Cordon-Cardo C., Renault B., Satagopan J.M.,
RA   Murty V.V., Massague J.;
RT   "Type I transforming growth factor beta receptor maps to 9q22 and
RT   exhibits a polymorphism and a rare variant within a polyalanine
RT   tract.";
RL   Cancer Res. 58:2727-2732(1998).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), NUCLEOTIDE SEQUENCE [MRNA] OF
RP   61-155 (ISOFORM 1), AND ALTERNATIVE SPLICING.
RC   TISSUE=Prostate;
RX   PubMed=17845732; DOI=10.1186/1471-2164-8-318;
RA   Konrad L., Scheiber J.A., Volck-Badouin E., Keilani M.M., Laible L.,
RA   Brandt H., Schmidt A., Aumuller G., Hofmann R.;
RT   "Alternative splicing of TGF-betas and their high-affinity receptors T
RT   beta RI, T beta RII and T beta RIII (betaglycan) reveal new variants
RT   in human prostatic cells.";
RL   BMC Genomics 8:318-318(2007).
RN   [9]
RP   SEQUENCE REVISION (ISOFORM 1).
RA   Konrad L.;
RL   Submitted (MAR-2011) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   FUNCTION, PHOSPHORYLATION AT THR-185; THR-186; SER-187; SER-189 AND
RP   SER-191 BY TGFBR2, SUBCELLULAR LOCATION, SUBUNIT, AND MUTAGENESIS OF
RP   185-THR-THR-186; SER-187; SER-189; SER-191; THR-200 AND THR-204.
RX   PubMed=7774578;
RA   Wieser R., Wrana J.L., Massague J.;
RT   "GS domain mutations that constitutively activate T beta R-I, the
RT   downstream signaling component in the TGF-beta receptor complex.";
RL   EMBO J. 14:2199-2208(1995).
RN   [11]
RP   FUNCTION IN PHOSPHORYLATION OF SMAD2.
RX   PubMed=8752209; DOI=10.1016/S0092-8674(00)80128-2;
RA   Eppert K., Scherer S.W., Ozcelik H., Pirone R., Hoodless P., Kim H.,
RA   Tsui L.-C., Bapat B., Gallinger S., Andrulis I.L., Thomsen G.H.,
RA   Wrana J.L., Attisano L.;
RT   "MADR2 maps to 18q21 and encodes a TGFbeta-regulated MAD-related
RT   protein that is functionally mutated in colorectal carcinoma.";
RL   Cell 86:543-552(1996).
RN   [12]
RP   INTERACTION WITH SMAD2, FUNCTION IN PHOSPHORYLATION OF SMAD2, AND
RP   FUNCTION IN TRANSCRIPTION REGULATION.
RX   PubMed=8980228; DOI=10.1016/S0092-8674(00)81817-6;
RA   Macias-Silva M., Abdollah S., Hoodless P.A., Pirone R., Attisano L.,
RA   Wrana J.L.;
RT   "MADR2 is a substrate of the TGFbeta receptor and its phosphorylation
RT   is required for nuclear accumulation and signaling.";
RL   Cell 87:1215-1224(1996).
RN   [13]
RP   INTERACTION WITH FKBP1A, ENZYME REGULATION, AND MUTAGENESIS OF LEU-193
RP   AND PRO-194.
RX   PubMed=9233797; DOI=10.1093/emboj/16.13.3866;
RA   Chen Y.G., Liu F., Massague J.;
RT   "Mechanism of TGFbeta receptor inhibition by FKBP12.";
RL   EMBO J. 16:3866-3876(1997).
RN   [14]
RP   INTERACTION WITH SMAD3.
RX   PubMed=9311995; DOI=10.1093/emboj/16.17.5353;
RA   Nakao A., Imamura T., Souchelnytskyi S., Kawabata M., Ishisaki A.,
RA   Oeda E., Tamaki K., Hanai J., Heldin C.H., Miyazono K., ten Dijke P.;
RT   "TGF-beta receptor-mediated signalling through Smad2, Smad3 and
RT   Smad4.";
RL   EMBO J. 16:5353-5362(1997).
RN   [15]
RP   INTERACTION WITH SMAD2, FUNCTION IN PHOSPHORYLATION OF SMAD2, AND
RP   FUNCTION IN TRANSCRIPTION REGULATION.
RX   PubMed=9346908; DOI=10.1074/jbc.272.44.27678;
RA   Abdollah S., Macias-Silva M., Tsukazaki T., Hayashi H., Attisano L.,
RA   Wrana J.L.;
RT   "TbetaRI phosphorylation of Smad2 on Ser465 and Ser467 is required for
RT   Smad2-Smad4 complex formation and signaling.";
RL   J. Biol. Chem. 272:27678-27685(1997).
RN   [16]
RP   INTERACTION WITH ZFYVE9.
RX   PubMed=9865696; DOI=10.1016/S0092-8674(00)81701-8;
RA   Tsukazaki T., Chiang T.A., Davison A.F., Attisano L., Wrana J.L.;
RT   "SARA, a FYVE domain protein that recruits Smad2 to the TGFbeta
RT   receptor.";
RL   Cell 95:779-791(1998).
RN   [17]
RP   HOMODIMERIZATION, AND SUBCELLULAR LOCATION.
RX   PubMed=9472030; DOI=10.1083/jcb.140.4.767;
RA   Gilboa L., Wells R.G., Lodish H.F., Henis Y.I.;
RT   "Oligomeric structure of type I and type II transforming growth factor
RT   beta receptors: homodimers form in the ER and persist at the plasma
RT   membrane.";
RL   J. Cell Biol. 140:767-777(1998).
RN   [18]
RP   INTERACTION WITH SMAD7 AND SMURF2, AND PROTEASOMAL AND LYSOSOMAL
RP   DEGRADATION.
RX   PubMed=11163210; DOI=10.1016/S1097-2765(00)00134-9;
RA   Kavsak P., Rasmussen R.K., Causing C.G., Bonni S., Zhu H.,
RA   Thomsen G.H., Wrana J.L.;
RT   "Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the
RT   TGF-beta receptor for degradation.";
RL   Mol. Cell 6:1365-1375(2000).
RN   [19]
RP   INTERACTION WITH SMAD7 AND SMURF1, AND PROTEASOMAL DEGRADATION.
RX   PubMed=11278251; DOI=10.1074/jbc.C100008200;
RA   Ebisawa T., Fukuchi M., Murakami G., Chiba T., Tanaka K., Imamura T.,
RA   Miyazono K.;
RT   "Smurf1 interacts with transforming growth factor-beta type I receptor
RT   through Smad7 and induces receptor degradation.";
RL   J. Biol. Chem. 276:12477-12480(2001).
RN   [20]
RP   INTERACTION WITH VPS39.
RX   PubMed=12941698; DOI=10.1093/emboj/cdg428;
RA   Felici A., Wurthner J.U., Parks W.T., Giam L.R., Reiss M.,
RA   Karpova T.S., McNally J.G., Roberts A.B.;
RT   "TLP, a novel modulator of TGF-beta signaling, has opposite effects on
RT   Smad2- and Smad3-dependent signaling.";
RL   EMBO J. 22:4465-4477(2003).
RN   [21]
RP   INTERACTION WITH NEDD4L, AND UBIQUITINATION.
RX   PubMed=15496141; DOI=10.1042/BJ20040738;
RA   Kuratomi G., Komuro A., Goto K., Shinozaki M., Miyazawa K.,
RA   Miyazono K., Imamura T.;
RT   "NEDD4-2 (neural precursor cell expressed, developmentally down-
RT   regulated 4-2) negatively regulates TGF-beta (transforming growth
RT   factor-beta) signalling by inducing ubiquitin-mediated degradation of
RT   Smad2 and TGF-beta type I receptor.";
RL   Biochem. J. 386:461-470(2005).
RN   [22]
RP   FUNCTION IN EPITHELIAL TO MESENCHYMAL TRANSITION, SUBCELLULAR
RP   LOCATION, INTERACTION WITH PARD6A, AND FUNCTION IN PHOSPHORYLATION OF
RP   PARD6A.
RX   PubMed=15761148; DOI=10.1126/science.1105718;
RA   Ozdamar B., Bose R., Barrios-Rodiles M., Wang H.R., Zhang Y.,
RA   Wrana J.L.;
RT   "Regulation of the polarity protein Par6 by TGFbeta receptors controls
RT   epithelial cell plasticity.";
RL   Science 307:1603-1609(2005).
RN   [23]
RP   FUNCTION IN CELLULAR GROWTH INHIBITION, AND INTERACTION WITH CD109.
RX   PubMed=16754747; DOI=10.1096/fj.05-5229fje;
RA   Finnson K.W., Tam B.Y.Y., Liu K., Marcoux A., Lepage P., Roy S.,
RA   Bizet A.A., Philip A.;
RT   "Identification of CD109 as part of the TGF-beta receptor system in
RT   human keratinocytes.";
RL   FASEB J. 20:1525-1527(2006).
RN   [24]
RP   INTERACTION WITH RBPMS.
RX   PubMed=17099224; DOI=10.1093/nar/gkl914;
RA   Sun Y., Ding L., Zhang H., Han J., Yang X., Yan J., Zhu Y., Li J.,
RA   Song H., Ye Q.;
RT   "Potentiation of Smad-mediated transcriptional activation by the RNA-
RT   binding protein RBPMS.";
RL   Nucleic Acids Res. 34:6314-6326(2006).
RN   [25]
RP   FUNCTION IN APOPTOSIS, AND INTERACTION WITH TRAF6 AND MAP3K7.
RX   PubMed=18758450; DOI=10.1038/ncb1780;
RA   Sorrentino A., Thakur N., Grimsby S., Marcusson A., von Bulow V.,
RA   Schuster N., Zhang S., Heldin C.H., Landstrom M.;
RT   "The type I TGF-beta receptor engages TRAF6 to activate TAK1 in a
RT   receptor kinase-independent manner.";
RL   Nat. Cell Biol. 10:1199-1207(2008).
RN   [26]
RP   REVIEW ON PROCESSES REGULATED BY THE TGF-BETA CYTOKINES.
RX   PubMed=9759503; DOI=10.1146/annurev.biochem.67.1.753;
RA   Massague J.;
RT   "TGF-beta signal transduction.";
RL   Annu. Rev. Biochem. 67:753-791(1998).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-165, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [28]
RP   UBIQUITINATION, AND DEUBIQUITINATION BY USP15.
RX   PubMed=22344298; DOI=10.1038/nm.2619;
RA   Eichhorn P.J., Rodon L., Gonzalez-Junca A., Dirac A., Gili M.,
RA   Martinez-Saez E., Aura C., Barba I., Peg V., Prat A., Cuartas I.,
RA   Jimenez J., Garcia-Dorado D., Sahuquillo J., Bernards R., Baselga J.,
RA   Seoane J.;
RT   "USP15 stabilizes TGF-beta receptor I and promotes oncogenesis through
RT   the activation of TGF-beta signaling in glioblastoma.";
RL   Nat. Med. 18:429-435(2012).
RN   [29]
RP   INTERACTION WITH SDCBP AND CAV1, SUBCELLULAR LOCATION, TISSUE
RP   SPECIFICITY, UBIQUITINATION, AND PROTEASOMAL DEGRADATION.
RX   PubMed=25893292; DOI=10.1038/onc.2015.100;
RA   Hwangbo C., Tae N., Lee S., Kim O., Park O.K., Kim J., Kwon S.H.,
RA   Lee J.H.;
RT   "Syntenin regulates TGF-beta1-induced Smad activation and the
RT   epithelial-to-mesenchymal transition by inhibiting caveolin-mediated
RT   TGF-beta type I receptor internalization.";
RL   Oncogene 35:389-401(2016).
RN   [30]
RP   3D-STRUCTURE MODELING OF 34-114.
RX   PubMed=8521960; DOI=10.1016/0014-5793(95)01239-7;
RA   Jokiranta T.S., Tissari J., Teleman O., Meri S.;
RT   "Extracellular domain of type I receptor for transforming growth
RT   factor-beta: molecular modelling using protectin (CD59) as a
RT   template.";
RL   FEBS Lett. 376:31-36(1995).
RN   [31]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 162-503 IN COMPLEX WITH
RP   FKBP1A.
RX   PubMed=10025408; DOI=10.1016/S0092-8674(00)80555-3;
RA   Huse M., Chen Y.-G., Massague J., Kuriyan J.;
RT   "Crystal structure of the cytoplasmic domain of the type I TGF beta
RT   receptor in complex with FKBP12.";
RL   Cell 96:425-436(1999).
RN   [32]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 162-503, PHOSPHORYLATION, AND
RP   INTERACTION WITH SMAD2 AND FKBP1A.
RX   PubMed=11583628; DOI=10.1016/S1097-2765(01)00332-X;
RA   Huse M., Muir T.W., Xu L., Chen Y.-G., Kuriyan J., Massague J.;
RT   "The TGF beta receptor activation process: an inhibitor- to substrate-
RT   binding switch.";
RL   Mol. Cell 8:671-682(2001).
RN   [33]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 175-500 IN COMPLEX WITH
RP   SYNTHETIC INHIBITOR.
RX   PubMed=15177479; DOI=10.1016/j.bmcl.2004.04.007;
RA   Sawyer J.S., Beight D.W., Britt K.S., Anderson B.D., Campbell R.M.,
RA   Goodson T. Jr., Herron D.K., Li H.-Y., McMillen W.T., Mort N.,
RA   Parsons S., Smith E.C.R., Wagner J.R., Yan L., Zhang F.,
RA   Yingling J.M.;
RT   "Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-
RT   dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming
RT   growth factor-beta type I receptor kinase domain.";
RL   Bioorg. Med. Chem. Lett. 14:3581-3584(2004).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 201-503 IN COMPLEX WITH
RP   SYNTHETIC INHIBITOR.
RX   PubMed=15317461; DOI=10.1021/jm0400247;
RA   Gellibert F., Woolven J., Fouchet M.-H., Mathews N., Goodland H.,
RA   Lovegrove V., Laroze A., Nguyen V.-L., Sautet S., Wang R., Janson C.,
RA   Smith W., Krysa G., Boullay V., De Gouville A.-C., Huet S.,
RA   Hartley D.;
RT   "Identification of 1,5-naphthyridine derivatives as a novel series of
RT   potent and selective TGF-beta type I receptor inhibitors.";
RL   J. Med. Chem. 47:4494-4506(2004).
RN   [35]
RP   X-RAY CRYSTALLOGRAPHY (3.00 ANGSTROMS) OF 33-111 IN COMPLEX WITH
RP   TGFBR2 AND TGFB3, AND DISULFIDE BONDS.
RX   PubMed=18243111; DOI=10.1016/j.molcel.2007.11.039;
RA   Groppe J., Hinck C.S., Samavarchi-Tehrani P., Zubieta C.,
RA   Schuermann J.P., Taylor A.B., Schwarz P.M., Wrana J.L., Hinck A.P.;
RT   "Cooperative assembly of TGF-beta superfamily signaling complexes is
RT   mediated by two disparate mechanisms and distinct modes of receptor
RT   binding.";
RL   Mol. Cell 29:157-168(2008).
RN   [36]
RP   X-RAY CRYSTALLOGRAPHY (3.00 ANGSTROMS) OF 31-115 IN COMPLEX WITH
RP   TGFBR2 AND TGFB1, RECEPTOR AFFINITY FOR LIGANDS, AND DISULFIDE BONDS.
RX   PubMed=20207738; DOI=10.1074/jbc.M109.079921;
RA   Radaev S., Zou Z., Huang T., Lafer E.M., Hinck A.P., Sun P.D.;
RT   "Ternary complex of transforming growth factor-beta1 reveals isoform-
RT   specific ligand recognition and receptor recruitment in the
RT   superfamily.";
RL   J. Biol. Chem. 285:14806-14814(2010).
RN   [37]
RP   ANALYSIS OF VARIANT TGFBR1*6A ALA-24--26-ALA DEL IN CANCER RISK.
RX   PubMed=12947057; DOI=10.1200/JCO.2003.11.524;
RA   Kaklamani V.G., Hou N., Bian Y., Reich J., Offit K., Michel L.S.,
RA   Rubinstein W.S., Rademaker A., Pasche B.;
RT   "TGFBR1*6A and cancer risk: a meta-analysis of seven case-control
RT   studies.";
RL   J. Clin. Oncol. 21:3236-3243(2003).
RN   [38]
RP   ANALYSIS OF VARIANT TGFBR1*6A ALA-24--26-ALA DEL IN PROSTATE CANCER.
RX   PubMed=15385056; DOI=10.1186/1471-2156-5-28;
RA   Kaklamani V.G., Baddi L., Rosman D., Liu J., Ellis N., Oddoux C.,
RA   Ostrer H., Chen Y., Ahsan H., Offit K., Pasche B.;
RT   "No major association between TGFBR1*6A and prostate cancer.";
RL   BMC Genet. 5:28-28(2004).
RN   [39]
RP   VARIANTS LDS1 ILE-200; ARG-318; GLY-400 AND PRO-487.
RX   PubMed=15731757; DOI=10.1038/ng1511;
RA   Loeys B.L., Chen J., Neptune E.R., Judge D.P., Podowski M., Holm T.,
RA   Meyers J., Leitch C.C., Katsanis N., Sharifi N., Xu F.L., Myers L.A.,
RA   Spevak P.J., Cameron D.E., De Backer J.F., Hellemans J., Chen Y.,
RA   Davis E.C., Webb C.L., Kress W., Coucke P.J., Rifkin D.B.,
RA   De Paepe A.M., Dietz H.C.;
RT   "A syndrome of altered cardiovascular, craniofacial, neurocognitive
RT   and skeletal development caused by mutations in TGFBR1 or TGFBR2.";
RL   Nat. Genet. 37:275-281(2005).
RN   [40]
RP   ANALYSIS OF VARIANT TGFBR1*6A ALA-24--26-ALA DEL IN PROSTATE CANCER.
RX   PubMed=15505640; DOI=10.1038/sj.pcan.4500765;
RA   Suarez B.K., Pal P., Jin C.H., Kaushal R., Sun G., Jin L., Pasche B.,
RA   Deka R., Catalona W.J.;
RT   "TGFBR1(*)6A is not associated with prostate cancer in men of European
RT   ancestry.";
RL   Prostate Cancer Prostatic Dis. 8:50-53(2005).
RN   [41]
RP   VARIANT LDS1 LEU-241.
RX   PubMed=16596670; DOI=10.1002/ajmg.a.31202;
RA   Ades L.C., Sullivan K., Biggin A., Haan E.A., Brett M., Holman K.J.,
RA   Dixon J., Robertson S., Holmes A.D., Rogers J., Bennetts B.;
RT   "FBN1, TGFBR1, and the Marfan-craniosynostosis/mental retardation
RT   disorders revisited.";
RL   Am. J. Med. Genet. A 140:1047-1058(2006).
RN   [42]
RP   VARIANTS LDS1 LEU-241 AND GLN-487, AND VARIANT HIS-267.
RX   PubMed=16791849; DOI=10.1002/humu.20353;
RA   Matyas G., Arnold E., Carrel T., Baumgartner D., Boileau C.,
RA   Berger W., Steinmann B.;
RT   "Identification and in silico analyses of novel TGFBR1 and TGFBR2
RT   mutations in Marfan syndrome-related disorders.";
RL   Hum. Mutat. 27:760-769(2006).
RN   [43]
RP   VARIANTS LDS1 GLU-232; TRP-487; PRO-487 AND GLN-487.
RX   PubMed=16928994; DOI=10.1056/NEJMoa055695;
RA   Loeys B.L., Schwarze U., Holm T., Callewaert B.L., Thomas G.H.,
RA   Pannu H., De Backer J.F., Oswald G.L., Symoens S., Manouvrier S.,
RA   Roberts A.E., Faravelli F., Greco M.A., Pyeritz R.E., Milewicz D.M.,
RA   Coucke P.J., Cameron D.E., Braverman A.C., Byers P.H., De Paepe A.M.,
RA   Dietz H.C.;
RT   "Aneurysm syndromes caused by mutations in the TGF-beta receptor.";
RL   N. Engl. J. Med. 355:788-798(2006).
RN   [44]
RP   VARIANTS [LARGE SCALE ANALYSIS] ILE-153 AND CYS-291.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [45]
RP   VARIANT [LARGE SCALE ANALYSIS] VAL-139.
RX   PubMed=18987736; DOI=10.1038/nature07485;
RA   Ley T.J., Mardis E.R., Ding L., Fulton B., McLellan M.D., Chen K.,
RA   Dooling D., Dunford-Shore B.H., McGrath S., Hickenbotham M., Cook L.,
RA   Abbott R., Larson D.E., Koboldt D.C., Pohl C., Smith S., Hawkins A.,
RA   Abbott S., Locke D., Hillier L.W., Miner T., Fulton L., Magrini V.,
RA   Wylie T., Glasscock J., Conyers J., Sander N., Shi X., Osborne J.R.,
RA   Minx P., Gordon D., Chinwalla A., Zhao Y., Ries R.E., Payton J.E.,
RA   Westervelt P., Tomasson M.H., Watson M., Baty J., Ivanovich J.,
RA   Heath S., Shannon W.D., Nagarajan R., Walter M.J., Link D.C.,
RA   Graubert T.A., DiPersio J.F., Wilson R.K.;
RT   "DNA sequencing of a cytogenetically normal acute myeloid leukaemia
RT   genome.";
RL   Nature 456:66-72(2008).
RN   [46]
RP   VARIANT LDS1 GLY-351.
RX   PubMed=19883511; DOI=10.1186/1750-1172-4-24;
RA   Drera B., Ritelli M., Zoppi N., Wischmeijer A., Gnoli M., Fattori R.,
RA   Calzavara-Pinton P.G., Barlati S., Colombi M.;
RT   "Loeys-Dietz syndrome type I and type II: clinical findings and novel
RT   mutations in two Italian patients.";
RL   Orphanet J. Rare Dis. 4:24-24(2009).
RN   [47]
RP   VARIANTS LDS1 TYR-266; ARG-375 AND GLN-487.
RX   PubMed=22113417; DOI=10.1038/jhg.2011.130;
RA   Yang J.H., Ki C.S., Han H., Song B.G., Jang S.Y., Chung T.Y., Sung K.,
RA   Lee H.J., Kim D.K.;
RT   "Clinical features and genetic analysis of Korean patients with Loeys-
RT   Dietz syndrome.";
RL   J. Hum. Genet. 57:52-56(2012).
RN   [48]
RP   ERRATUM.
RA   Yang J.H., Ki C.S., Han H., Song B.G., Jang S.Y., Chung T.Y., Sung K.,
RA   Lee H.J., Kim D.K.;
RL   J. Hum. Genet. 57:398-398(2012).
RN   [49]
RP   VARIANTS MSSE TYR-41; SER-45; ARG-52 AND LEU-83.
RX   PubMed=21358634; DOI=10.1038/ng.780;
RA   Goudie D.R., D'Alessandro M., Merriman B., Lee H., Szeverenyi I.,
RA   Avery S., O'Connor B.D., Nelson S.F., Coats S.E., Stewart A.,
RA   Christie L., Pichert G., Friedel J., Hayes I., Burrows N.,
RA   Whittaker S., Gerdes A.M., Broesby-Olsen S., Ferguson-Smith M.A.,
RA   Verma C., Lunny D.P., Reversade B., Lane E.B.;
RT   "Multiple self-healing squamous epithelioma is caused by a disease-
RT   specific spectrum of mutations in TGFBR1.";
RL   Nat. Genet. 43:365-369(2011).
CC   -!- FUNCTION: Transmembrane serine/threonine kinase forming with the
CC       TGF-beta type II serine/threonine kinase receptor, TGFBR2, the
CC       non-promiscuous receptor for the TGF-beta cytokines TGFB1, TGFB2
CC       and TGFB3. Transduces the TGFB1, TGFB2 and TGFB3 signal from the
CC       cell surface to the cytoplasm and is thus regulating a plethora of
CC       physiological and pathological processes including cell cycle
CC       arrest in epithelial and hematopoietic cells, control of
CC       mesenchymal cell proliferation and differentiation, wound healing,
CC       extracellular matrix production, immunosuppression and
CC       carcinogenesis. The formation of the receptor complex composed of
CC       2 TGFBR1 and 2 TGFBR2 molecules symmetrically bound to the
CC       cytokine dimer results in the phosphorylation and the activation
CC       of TGFBR1 by the constitutively active TGFBR2. Activated TGFBR1
CC       phosphorylates SMAD2 which dissociates from the receptor and
CC       interacts with SMAD4. The SMAD2-SMAD4 complex is subsequently
CC       translocated to the nucleus where it modulates the transcription
CC       of the TGF-beta-regulated genes. This constitutes the canonical
CC       SMAD-dependent TGF-beta signaling cascade. Also involved in non-
CC       canonical, SMAD-independent TGF-beta signaling pathways. For
CC       instance, TGFBR1 induces TRAF6 autoubiquitination which in turn
CC       results in MAP3K7 ubiquitination and activation to trigger
CC       apoptosis. Also regulates epithelial to mesenchymal transition
CC       through a SMAD-independent signaling pathway through PARD6A
CC       phosphorylation and activation. {ECO:0000269|PubMed:15761148,
CC       ECO:0000269|PubMed:16754747, ECO:0000269|PubMed:18758450,
CC       ECO:0000269|PubMed:7774578, ECO:0000269|PubMed:8752209,
CC       ECO:0000269|PubMed:8980228, ECO:0000269|PubMed:9346908}.
CC   -!- CATALYTIC ACTIVITY: ATP + [receptor-protein] = ADP + [receptor-
CC       protein] phosphate.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035; Evidence={ECO:0000250};
CC   -!- ENZYME REGULATION: Kept in an inactive conformation by FKBP1A
CC       preventing receptor activation in absence of ligand. CD109 is
CC       another inhibitor of the receptor. {ECO:0000269|PubMed:9233797}.
CC   -!- SUBUNIT: Homodimer; in the endoplasmic reticulum but also at the
CC       cell membrane. Heterohexamer; TGFB1, TGFB2 and TGFB3 homodimeric
CC       ligands assemble a functional receptor composed of two TGFBR1 and
CC       TGFBR2 heterodimers to form a ligand-receptor heterohexamer. The
CC       respective affinity of TGBRB1 and TGFBR2 for the ligands may
CC       modulate the kinetics of assembly of the receptor and may explain
CC       the different biological activities of TGFB1, TGFB2 and TGFB3.
CC       Interacts with CD109; inhibits TGF-beta receptor activation in
CC       keratinocytes. Interacts with RBPMS. Interacts (unphosphorylated)
CC       with FKBP1A; prevents TGFBR1 phosphorylation by TGFBR2 and
CC       stabilizes it in the inactive conformation. Interacts with SMAD2,
CC       SMAD3 and ZFYVE9; ZFYVE9 recruits SMAD2 and SMAD3 to the TGF-beta
CC       receptor. Interacts with TRAF6 and MAP3K7; induces MAP3K7
CC       activation by TRAF6. Interacts with PARD6A; involved in TGF-beta
CC       induced epithelial to mesenchymal transition. Interacts with
CC       SMAD7, NEDD4L, SMURF1 and SMURF2; SMAD7 recruits NEDD4L, SMURF1
CC       and SMURF2 to the TGF-beta receptor. Interacts with USP15 and
CC       VPS39. Interacts with SDCBP (via C-terminus) (PubMed:25893292)
CC       Interacts with CAV1 and this interaction is impaired in the
CC       presence of SDCBP (PubMed:25893292). {ECO:0000269|PubMed:10025408,
CC       ECO:0000269|PubMed:11163210, ECO:0000269|PubMed:11278251,
CC       ECO:0000269|PubMed:11583628, ECO:0000269|PubMed:12941698,
CC       ECO:0000269|PubMed:15177479, ECO:0000269|PubMed:15317461,
CC       ECO:0000269|PubMed:15496141, ECO:0000269|PubMed:15761148,
CC       ECO:0000269|PubMed:16754747, ECO:0000269|PubMed:17099224,
CC       ECO:0000269|PubMed:18243111, ECO:0000269|PubMed:18758450,
CC       ECO:0000269|PubMed:20207738, ECO:0000269|PubMed:25893292,
CC       ECO:0000269|PubMed:7774578, ECO:0000269|PubMed:8980228,
CC       ECO:0000269|PubMed:9233797, ECO:0000269|PubMed:9311995,
CC       ECO:0000269|PubMed:9346908, ECO:0000269|PubMed:9865696}.
CC   -!- INTERACTION:
CC       Q99IB8:- (xeno); NbExp=5; IntAct=EBI-1027557, EBI-6858501;
CC       P62942:FKBP1A; NbExp=2; IntAct=EBI-1027557, EBI-1027571;
CC       P01137:TGFB1; NbExp=2; IntAct=EBI-1027557, EBI-779636;
CC       P63104:YWHAZ; NbExp=4; IntAct=EBI-1027557, EBI-347088;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:25893292,
CC       ECO:0000269|PubMed:9472030}; Single-pass type I membrane protein
CC       {ECO:0000269|PubMed:9472030}. Cell junction, tight junction
CC       {ECO:0000269|PubMed:15761148}. Cell surface
CC       {ECO:0000269|PubMed:25893292}. Membrane raft
CC       {ECO:0000269|PubMed:25893292}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P36897-1; Sequence=Displayed;
CC       Name=2; Synonyms=B;
CC         IsoId=P36897-2; Sequence=VSP_041326;
CC       Name=3;
CC         IsoId=P36897-3; Sequence=VSP_041327;
CC   -!- TISSUE SPECIFICITY: Found in all tissues examined, most abundant
CC       in placenta and least abundant in brain and heart. Expressed in a
CC       variety of cancer cell lines (PubMed:25893292).
CC       {ECO:0000269|PubMed:25893292}.
CC   -!- PTM: Phosphorylated at basal levels in the absence of ligand.
CC       Activated upon phosphorylation by TGFBR2, mainly in the GS domain.
CC       Phosphorylation in the GS domain abrogates FKBP1A-binding.
CC       {ECO:0000269|PubMed:11583628, ECO:0000269|PubMed:7774578}.
CC   -!- PTM: N-Glycosylated. {ECO:0000269|PubMed:9661882}.
CC   -!- PTM: Ubiquitinated; undergoes ubiquitination catalyzed by several
CC       E3 ubiquitin ligases including SMURF1, SMURF2 and NEDD4L2. Results
CC       in the proteasomal and/or lysosomal degradation of the receptor
CC       thereby negatively regulating its activity. Deubiquitinated by
CC       USP15, leading to stabilization of the protein and enhanced TGF-
CC       beta signal. Its ubiquitination and proteasome-mediated
CC       degradation is negatively regulated by SDCBP (PubMed:25893292).
CC       {ECO:0000269|PubMed:15496141, ECO:0000269|PubMed:22344298,
CC       ECO:0000269|PubMed:25893292}.
CC   -!- DISEASE: Loeys-Dietz syndrome 1 (LDS1) [MIM:609192]: An aortic
CC       aneurysm syndrome with widespread systemic involvement,
CC       characterized by arterial tortuosity and aneurysms, hypertelorism,
CC       and bifid uvula or cleft palate. Physical findings include
CC       prominent joint laxity, easy bruising, wide and atrophic scars,
CC       velvety and translucent skin with easily visible veins,
CC       spontaneous rupture of the spleen or bowel, and catastrophic
CC       complications of pregnancy, including rupture of the gravid uterus
CC       and the arteries, either during pregnancy or in the immediate
CC       postpartum period. Some patients have craniosynostosis, exotropy,
CC       micrognathia and retrognathia, structural brain abnormalities, and
CC       intellectual deficit. {ECO:0000269|PubMed:15731757,
CC       ECO:0000269|PubMed:16596670, ECO:0000269|PubMed:16791849,
CC       ECO:0000269|PubMed:16928994, ECO:0000269|PubMed:19883511,
CC       ECO:0000269|PubMed:22113417}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry. TGFBR1
CC       mutation Gln-487 has been reported to be associated with thoracic
CC       aortic aneurysms and dissection (TAAD) (PubMed:16791849). This
CC       phenotype, also known as thoracic aortic aneurysms type 5 (AAT5),
CC       is distinguised from LDS1 by having aneurysms restricted to
CC       thoracic aorta. It is unclear, however, if this condition is
CC       fulfilled in individuals bearing Gln-487 mutation, that is why
CC       they are considered as LDS1 by the OMIM resource.
CC       {ECO:0000269|PubMed:16791849}.
CC   -!- DISEASE: Multiple self-healing squamous epithelioma (MSSE)
CC       [MIM:132800]: A disorder characterized by multiple skin tumors
CC       that undergo spontaneous regression. Tumors appear most often on
CC       sun-exposed regions, are locally invasive, and undergo spontaneous
CC       resolution over a period of months leaving pitted scars.
CC       {ECO:0000269|PubMed:21358634}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr
CC       protein kinase family. TGFB receptor subfamily. {ECO:0000305}.
CC   -!- CAUTION: One report originally reported variant Ile-375
CC       (PubMed:22113417). This variant has been subsequently corrected to
CC       Arg-375 by the same authors (Ref.48).
CC       {ECO:0000269|PubMed:22113417, ECO:0000269|Ref.48}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/tgfbr1/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L11695; AAA16073.1; -; mRNA.
DR   EMBL; AF054598; AAC08998.1; -; Genomic_DNA.
DR   EMBL; AF054590; AAC08998.1; JOINED; Genomic_DNA.
DR   EMBL; AF054591; AAC08998.1; JOINED; Genomic_DNA.
DR   EMBL; AF054592; AAC08998.1; JOINED; Genomic_DNA.
DR   EMBL; AF054593; AAC08998.1; JOINED; Genomic_DNA.
DR   EMBL; AF054594; AAC08998.1; JOINED; Genomic_DNA.
DR   EMBL; AF054595; AAC08998.1; JOINED; Genomic_DNA.
DR   EMBL; AF054596; AAC08998.1; JOINED; Genomic_DNA.
DR   EMBL; AF054597; AAC08998.1; JOINED; Genomic_DNA.
DR   EMBL; AF035670; AAD02042.1; -; Genomic_DNA.
DR   EMBL; AF035662; AAD02042.1; JOINED; Genomic_DNA.
DR   EMBL; AF035663; AAD02042.1; JOINED; Genomic_DNA.
DR   EMBL; AF035664; AAD02042.1; JOINED; Genomic_DNA.
DR   EMBL; AF035665; AAD02042.1; JOINED; Genomic_DNA.
DR   EMBL; AF035666; AAD02042.1; JOINED; Genomic_DNA.
DR   EMBL; AF035667; AAD02042.1; JOINED; Genomic_DNA.
DR   EMBL; AF035668; AAD02042.1; JOINED; Genomic_DNA.
DR   EMBL; AF035669; AAD02042.1; JOINED; Genomic_DNA.
DR   EMBL; AY497473; AAR32097.1; -; Genomic_DNA.
DR   EMBL; AL162427; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC071181; AAH71181.1; -; mRNA.
DR   EMBL; AJ619019; CAF02096.2; -; mRNA.
DR   EMBL; AJ619020; CAF02097.1; -; mRNA.
DR   CCDS; CCDS47998.1; -. [P36897-3]
DR   CCDS; CCDS6738.1; -. [P36897-1]
DR   CCDS; CCDS78413.1; -. [P36897-2]
DR   PIR; A49432; A49432.
DR   RefSeq; NP_001124388.1; NM_001130916.2. [P36897-3]
DR   RefSeq; NP_001293139.1; NM_001306210.1. [P36897-2]
DR   RefSeq; NP_004603.1; NM_004612.3. [P36897-1]
DR   UniGene; Hs.494622; -.
DR   PDB; 1B6C; X-ray; 2.60 A; B/D/F/H=162-503.
DR   PDB; 1IAS; X-ray; 2.90 A; A/B/C/D/E=162-503.
DR   PDB; 1PY5; X-ray; 2.30 A; A=175-500.
DR   PDB; 1RW8; X-ray; 2.40 A; A=200-500.
DR   PDB; 1TBI; Model; -; A=34-114.
DR   PDB; 1VJY; X-ray; 2.00 A; A=201-503.
DR   PDB; 2L5S; NMR; -; A=31-115.
DR   PDB; 2PJY; X-ray; 3.00 A; C=33-111.
DR   PDB; 2WOT; X-ray; 1.85 A; A=200-503.
DR   PDB; 2WOU; X-ray; 2.30 A; A=200-503.
DR   PDB; 2X7O; X-ray; 3.70 A; A/B/C/D/E=162-503.
DR   PDB; 3FAA; X-ray; 3.35 A; A/B/C/D/E=162-503.
DR   PDB; 3GXL; X-ray; 1.80 A; A=201-503.
DR   PDB; 3HMM; X-ray; 1.70 A; A=201-503.
DR   PDB; 3KCF; X-ray; 2.80 A; A/B/C/D/E=162-503.
DR   PDB; 3KFD; X-ray; 3.00 A; I/J/K/L=31-115.
DR   PDB; 3TZM; X-ray; 1.70 A; A=200-503.
DR   PDB; 4X0M; X-ray; 1.68 A; A=200-503.
DR   PDB; 4X2F; X-ray; 1.49 A; A=200-503.
DR   PDB; 4X2G; X-ray; 1.51 A; A=200-503.
DR   PDB; 4X2J; X-ray; 1.69 A; A=200-503.
DR   PDB; 4X2K; X-ray; 1.69 A; A=200-503.
DR   PDB; 4X2N; X-ray; 1.80 A; A=200-503.
DR   PDB; 5E8S; X-ray; 1.45 A; A=200-503.
DR   PDB; 5E8T; X-ray; 1.70 A; A=200-503.
DR   PDB; 5E8U; X-ray; 2.03 A; A=200-503.
DR   PDB; 5E8W; X-ray; 1.86 A; A=200-503.
DR   PDB; 5E8X; X-ray; 1.45 A; A=200-503.
DR   PDB; 5E8Z; X-ray; 1.51 A; A=200-503.
DR   PDB; 5E90; X-ray; 2.05 A; A=200-503.
DR   PDB; 5FRI; X-ray; 2.00 A; A=200-498.
DR   PDBsum; 1B6C; -.
DR   PDBsum; 1IAS; -.
DR   PDBsum; 1PY5; -.
DR   PDBsum; 1RW8; -.
DR   PDBsum; 1TBI; -.
DR   PDBsum; 1VJY; -.
DR   PDBsum; 2L5S; -.
DR   PDBsum; 2PJY; -.
DR   PDBsum; 2WOT; -.
DR   PDBsum; 2WOU; -.
DR   PDBsum; 2X7O; -.
DR   PDBsum; 3FAA; -.
DR   PDBsum; 3GXL; -.
DR   PDBsum; 3HMM; -.
DR   PDBsum; 3KCF; -.
DR   PDBsum; 3KFD; -.
DR   PDBsum; 3TZM; -.
DR   PDBsum; 4X0M; -.
DR   PDBsum; 4X2F; -.
DR   PDBsum; 4X2G; -.
DR   PDBsum; 4X2J; -.
DR   PDBsum; 4X2K; -.
DR   PDBsum; 4X2N; -.
DR   PDBsum; 5E8S; -.
DR   PDBsum; 5E8T; -.
DR   PDBsum; 5E8U; -.
DR   PDBsum; 5E8W; -.
DR   PDBsum; 5E8X; -.
DR   PDBsum; 5E8Z; -.
DR   PDBsum; 5E90; -.
DR   PDBsum; 5FRI; -.
DR   ProteinModelPortal; P36897; -.
DR   SMR; P36897; -.
DR   BioGrid; 112904; 182.
DR   DIP; DIP-5935N; -.
DR   IntAct; P36897; 16.
DR   MINT; MINT-152959; -.
DR   STRING; 9606.ENSP00000364133; -.
DR   BindingDB; P36897; -.
DR   ChEMBL; CHEMBL4439; -.
DR   DrugBank; DB07267; 2-(6-methylpyridin-2-yl)-N-pyridin-4-ylquinazolin-4-amine.
DR   DrugBank; DB03921; 4-(3-Pyridin-2-Yl-1h-Pyrazol-4-Yl)Quinoline.
DR   DrugBank; DB08450; N-1H-indazol-5-yl-2-(6-methylpyridin-2-yl)quinazolin-4-amine.
DR   DrugBank; DB07152; N-[4-(5-fluoro-6-methylpyridin-2-yl)-5-quinoxalin-6-yl-1H-imidazol-2-yl]acetamide.
DR   DrugBank; DB04434; Naphthyridine Inhibitor.
DR   GuidetoPHARMACOLOGY; 1788; -.
DR   iPTMnet; P36897; -.
DR   PhosphoSitePlus; P36897; -.
DR   BioMuta; TGFBR1; -.
DR   DMDM; 547777; -.
DR   EPD; P36897; -.
DR   PaxDb; P36897; -.
DR   PeptideAtlas; P36897; -.
DR   PRIDE; P36897; -.
DR   DNASU; 7046; -.
DR   Ensembl; ENST00000374990; ENSP00000364129; ENSG00000106799. [P36897-3]
DR   Ensembl; ENST00000374994; ENSP00000364133; ENSG00000106799. [P36897-1]
DR   Ensembl; ENST00000552516; ENSP00000447297; ENSG00000106799. [P36897-2]
DR   GeneID; 7046; -.
DR   KEGG; hsa:7046; -.
DR   UCSC; uc004azd.4; human. [P36897-1]
DR   CTD; 7046; -.
DR   DisGeNET; 7046; -.
DR   GeneCards; TGFBR1; -.
DR   GeneReviews; TGFBR1; -.
DR   HGNC; HGNC:11772; TGFBR1.
DR   HPA; CAB002441; -.
DR   HPA; CAB031481; -.
DR   HPA; HPA056473; -.
DR   MalaCards; TGFBR1; -.
DR   MIM; 132800; phenotype.
DR   MIM; 190181; gene.
DR   MIM; 609192; phenotype.
DR   neXtProt; NX_P36897; -.
DR   OpenTargets; ENSG00000106799; -.
DR   Orphanet; 91387; Familial thoracic aortic aneurysm and aortic dissection.
DR   Orphanet; 60030; Loeys-Dietz syndrome.
DR   Orphanet; 65748; Multiple keratoacanthoma, Ferguson-Smith type.
DR   PharmGKB; PA36485; -.
DR   eggNOG; KOG2052; Eukaryota.
DR   eggNOG; ENOG410XQT0; LUCA.
DR   GeneTree; ENSGT00760000118876; -.
DR   HOGENOM; HOG000230587; -.
DR   HOVERGEN; HBG054502; -.
DR   InParanoid; P36897; -.
DR   KO; K04674; -.
DR   OMA; GATALQC; -.
DR   OrthoDB; EOG091G0BIU; -.
DR   PhylomeDB; P36897; -.
DR   TreeFam; TF314724; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   BRENDA; 2.7.11.30; 2681.
DR   Reactome; R-HSA-2173788; Downregulation of TGF-beta receptor signaling.
DR   Reactome; R-HSA-2173789; TGF-beta receptor signaling activates SMADs.
DR   Reactome; R-HSA-2173791; TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition).
DR   Reactome; R-HSA-3304356; SMAD2/3 Phosphorylation Motif Mutants in Cancer.
DR   Reactome; R-HSA-3315487; SMAD2/3 MH2 Domain Mutants in Cancer.
DR   Reactome; R-HSA-3645790; TGFBR2 Kinase Domain Mutants in Cancer.
DR   Reactome; R-HSA-3656532; TGFBR1 KD Mutants in Cancer.
DR   Reactome; R-HSA-3656535; TGFBR1 LBD Mutants in Cancer.
DR   Reactome; R-HSA-5689603; UCH proteinases.
DR   Reactome; R-HSA-5689880; Ub-specific processing proteases.
DR   SignaLink; P36897; -.
DR   SIGNOR; P36897; -.
DR   ChiTaRS; TGFBR1; human.
DR   EvolutionaryTrace; P36897; -.
DR   GeneWiki; TGF_beta_receptor_1; -.
DR   GenomeRNAi; 7046; -.
DR   PRO; PR:P36897; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   Bgee; ENSG00000106799; -.
DR   CleanEx; HS_TGFBR1; -.
DR   ExpressionAtlas; P36897; baseline and differential.
DR   Genevisible; P36897; HS.
DR   GO; GO:0005923; C:bicellular tight junction; IDA:UniProtKB.
DR   GO; GO:0005623; C:cell; ISS:AgBase.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0005768; C:endosome; IEA:Ensembl.
DR   GO; GO:0005622; C:intracellular; IEA:GOC.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0016020; C:membrane; ISS:AgBase.
DR   GO; GO:0045121; C:membrane raft; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0043235; C:receptor complex; IDA:BHF-UCL.
DR   GO; GO:0070022; C:transforming growth factor beta receptor complex; IC:BHF-UCL.
DR   GO; GO:0005524; F:ATP binding; IDA:HGNC.
DR   GO; GO:0070411; F:I-SMAD binding; IPI:BHF-UCL.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004672; F:protein kinase activity; IDA:BHF-UCL.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:HGNC.
DR   GO; GO:0005057; F:signal transducer activity, downstream of receptor; ISS:AgBase.
DR   GO; GO:0004702; F:signal transducer, downstream of receptor, with serine/threonine kinase activity; IEA:Ensembl.
DR   GO; GO:0046332; F:SMAD binding; IDA:HGNC.
DR   GO; GO:0050431; F:transforming growth factor beta binding; IDA:BHF-UCL.
DR   GO; GO:0005025; F:transforming growth factor beta receptor activity, type I; IDA:BHF-UCL.
DR   GO; GO:0005024; F:transforming growth factor beta-activated receptor activity; IDA:BHF-UCL.
DR   GO; GO:0005114; F:type II transforming growth factor beta receptor binding; IDA:BHF-UCL.
DR   GO; GO:0000186; P:activation of MAPKK activity; IDA:BHF-UCL.
DR   GO; GO:0032924; P:activin receptor signaling pathway; ISS:AgBase.
DR   GO; GO:0060978; P:angiogenesis involved in coronary vascular morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0009952; P:anterior/posterior pattern specification; ISS:BHF-UCL.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0048844; P:artery morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0001824; P:blastocyst development; IEA:Ensembl.
DR   GO; GO:0060317; P:cardiac epithelial to mesenchymal transition; ISS:AgBase.
DR   GO; GO:0007050; P:cell cycle arrest; TAS:UniProtKB.
DR   GO; GO:0048870; P:cell motility; IMP:BHF-UCL.
DR   GO; GO:0071560; P:cellular response to transforming growth factor beta stimulus; IDA:BHF-UCL.
DR   GO; GO:0030199; P:collagen fibril organization; ISS:BHF-UCL.
DR   GO; GO:0060982; P:coronary artery morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0048701; P:embryonic cranial skeleton morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0042118; P:endothelial cell activation; ISS:AgBase.
DR   GO; GO:0043542; P:endothelial cell migration; IEA:Ensembl.
DR   GO; GO:1905223; P:epicardium morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0001837; P:epithelial to mesenchymal transition; IDA:UniProtKB.
DR   GO; GO:0043062; P:extracellular structure organization; TAS:UniProtKB.
DR   GO; GO:0008354; P:germ cell migration; ISS:BHF-UCL.
DR   GO; GO:0007507; P:heart development; ISS:AgBase.
DR   GO; GO:0001701; P:in utero embryonic development; ISS:BHF-UCL.
DR   GO; GO:0035556; P:intracellular signal transduction; ISS:AgBase.
DR   GO; GO:0001822; P:kidney development; ISS:BHF-UCL.
DR   GO; GO:0002088; P:lens development in camera-type eye; IEA:Ensembl.
DR   GO; GO:0008584; P:male gonad development; IEA:Ensembl.
DR   GO; GO:0048762; P:mesenchymal cell differentiation; ISS:AgBase.
DR   GO; GO:0032331; P:negative regulation of chondrocyte differentiation; ISS:BHF-UCL.
DR   GO; GO:0001937; P:negative regulation of endothelial cell proliferation; IEA:Ensembl.
DR   GO; GO:2001237; P:negative regulation of extrinsic apoptotic signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0030512; P:negative regulation of transforming growth factor beta receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0048663; P:neuron fate commitment; ISS:BHF-UCL.
DR   GO; GO:0060021; P:palate development; ISS:BHF-UCL.
DR   GO; GO:0060017; P:parathyroid gland development; ISS:BHF-UCL.
DR   GO; GO:0060389; P:pathway-restricted SMAD protein phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0018107; P:peptidyl-threonine phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0060037; P:pharyngeal system development; ISS:BHF-UCL.
DR   GO; GO:2001235; P:positive regulation of apoptotic signaling pathway; IDA:UniProtKB.
DR   GO; GO:0030307; P:positive regulation of cell growth; IDA:BHF-UCL.
DR   GO; GO:0030335; P:positive regulation of cell migration; IDA:BHF-UCL.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IMP:HGNC.
DR   GO; GO:0051272; P:positive regulation of cellular component movement; IMP:BHF-UCL.
DR   GO; GO:0001938; P:positive regulation of endothelial cell proliferation; ISS:AgBase.
DR   GO; GO:0010718; P:positive regulation of epithelial to mesenchymal transition; ISS:BHF-UCL.
DR   GO; GO:1905007; P:positive regulation of epithelial to mesenchymal transition involved in endocardial cushion formation; ISS:BHF-UCL.
DR   GO; GO:0051491; P:positive regulation of filopodium assembly; IEA:Ensembl.
DR   GO; GO:0010628; P:positive regulation of gene expression; ISS:AgBase.
DR   GO; GO:1905075; P:positive regulation of occluding junction disassembly; ISS:BHF-UCL.
DR   GO; GO:0010862; P:positive regulation of pathway-restricted SMAD protein phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0051897; P:positive regulation of protein kinase B signaling; IDA:BHF-UCL.
DR   GO; GO:0060391; P:positive regulation of SMAD protein import into nucleus; IDA:BHF-UCL.
DR   GO; GO:0051496; P:positive regulation of stress fiber assembly; ISS:BHF-UCL.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:BHF-UCL.
DR   GO; GO:0009791; P:post-embryonic development; IEA:Ensembl.
DR   GO; GO:0016579; P:protein deubiquitination; TAS:Reactome.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0060043; P:regulation of cardiac muscle cell proliferation; ISS:BHF-UCL.
DR   GO; GO:0010717; P:regulation of epithelial to mesenchymal transition; ISS:AgBase.
DR   GO; GO:0010468; P:regulation of gene expression; ISS:AgBase.
DR   GO; GO:0043393; P:regulation of protein binding; IEA:Ensembl.
DR   GO; GO:0031396; P:regulation of protein ubiquitination; IDA:UniProtKB.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IDA:HGNC.
DR   GO; GO:0070723; P:response to cholesterol; IDA:BHF-UCL.
DR   GO; GO:0007165; P:signal transduction; IDA:HGNC.
DR   GO; GO:0001501; P:skeletal system development; ISS:BHF-UCL.
DR   GO; GO:0048705; P:skeletal system morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0048538; P:thymus development; ISS:BHF-UCL.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0003223; P:ventricular compact myocardium morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0060412; P:ventricular septum morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0003222; P:ventricular trabecula myocardium morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0042060; P:wound healing; TAS:UniProtKB.
DR   InterPro; IPR000472; Activin_recp.
DR   InterPro; IPR003605; GS_dom.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   InterPro; IPR000333; TGFB_receptor.
DR   PANTHER; PTHR23255; PTHR23255; 1.
DR   Pfam; PF01064; Activin_recp; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF08515; TGF_beta_GS; 1.
DR   SMART; SM00467; GS; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS51256; GS; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Aortic aneurysm; Apoptosis;
KW   ATP-binding; Cell junction; Cell membrane; Complete proteome;
KW   Craniosynostosis; Differentiation; Direct protein sequencing;
KW   Disease mutation; Disulfide bond; Glycoprotein; Growth regulation;
KW   Isopeptide bond; Kinase; Magnesium; Manganese; Membrane;
KW   Metal-binding; Nucleotide-binding; Phosphoprotein; Polymorphism;
KW   Receptor; Reference proteome; Serine/threonine-protein kinase; Signal;
KW   Tight junction; Transferase; Transmembrane; Transmembrane helix;
KW   Ubl conjugation.
FT   SIGNAL        1     33       {ECO:0000269|PubMed:9661882}.
FT   CHAIN        34    503       TGF-beta receptor type-1.
FT                                /FTId=PRO_0000024423.
FT   TOPO_DOM     34    126       Extracellular. {ECO:0000255}.
FT   TRANSMEM    127    147       Helical. {ECO:0000255}.
FT   TOPO_DOM    148    503       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN      175    204       GS. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00585}.
FT   DOMAIN      205    495       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     211    219       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOTIF       193    194       FKBP1A-binding.
FT   ACT_SITE    333    333       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING     232    232       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES     165    165       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES     185    185       Phosphothreonine; by TGFBR2.
FT                                {ECO:0000269|PubMed:7774578}.
FT   MOD_RES     186    186       Phosphothreonine; by TGFBR2.
FT                                {ECO:0000269|PubMed:7774578}.
FT   MOD_RES     187    187       Phosphoserine; by TGFBR2.
FT                                {ECO:0000269|PubMed:7774578}.
FT   MOD_RES     189    189       Phosphoserine; by TGFBR2.
FT                                {ECO:0000269|PubMed:7774578}.
FT   MOD_RES     191    191       Phosphoserine; by TGFBR2.
FT                                {ECO:0000269|PubMed:7774578}.
FT   CARBOHYD     45     45       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   DISULFID     36     54       {ECO:0000269|PubMed:18243111,
FT                                ECO:0000269|PubMed:20207738}.
FT   DISULFID     38     41       {ECO:0000269|PubMed:18243111,
FT                                ECO:0000269|PubMed:20207738}.
FT   DISULFID     48     71       {ECO:0000269|PubMed:18243111,
FT                                ECO:0000269|PubMed:20207738}.
FT   DISULFID     86    100       {ECO:0000269|PubMed:18243111,
FT                                ECO:0000269|PubMed:20207738}.
FT   DISULFID    101    106       {ECO:0000269|PubMed:18243111,
FT                                ECO:0000269|PubMed:20207738}.
FT   CROSSLNK    391    391       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO).
FT                                {ECO:0000250}.
FT   VAR_SEQ     114    114       T -> TGPFS (in isoform 2).
FT                                {ECO:0000303|PubMed:17845732}.
FT                                /FTId=VSP_041326.
FT   VAR_SEQ     115    191       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_041327.
FT   VARIANT      24     26       Missing (in allele TGFBR1*6A; could be a
FT                                tumor susceptibility allele).
FT                                /FTId=VAR_022342.
FT   VARIANT      26     26       A -> AA (in allele TGFBR1*10A; rare
FT                                polymorphism).
FT                                {ECO:0000269|PubMed:9661882}.
FT                                /FTId=VAR_022343.
FT   VARIANT      41     41       C -> Y (in MSSE; hypomorphic mutation).
FT                                {ECO:0000269|PubMed:21358634}.
FT                                /FTId=VAR_065826.
FT   VARIANT      45     45       N -> S (in MSSE; hypomorphic mutation;
FT                                dbSNP:rs387906696).
FT                                {ECO:0000269|PubMed:21358634}.
FT                                /FTId=VAR_065827.
FT   VARIANT      52     52       G -> R (in MSSE; hypomorphic mutation;
FT                                dbSNP:rs587776865).
FT                                {ECO:0000269|PubMed:21358634}.
FT                                /FTId=VAR_065828.
FT   VARIANT      83     83       P -> L (in MSSE; hypomorphic mutation;
FT                                dbSNP:rs757374917).
FT                                {ECO:0000269|PubMed:21358634}.
FT                                /FTId=VAR_065829.
FT   VARIANT     139    139       I -> V (in dbSNP:rs148176750).
FT                                {ECO:0000269|PubMed:18987736}.
FT                                /FTId=VAR_054160.
FT   VARIANT     153    153       V -> I (in dbSNP:rs56014374).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041412.
FT   VARIANT     200    200       T -> I (in LDS1; dbSNP:rs121918712).
FT                                {ECO:0000269|PubMed:15731757}.
FT                                /FTId=VAR_022344.
FT   VARIANT     232    232       K -> E (in LDS1).
FT                                {ECO:0000269|PubMed:16928994}.
FT                                /FTId=VAR_029481.
FT   VARIANT     241    241       S -> L (in LDS1; dbSNP:rs111854391).
FT                                {ECO:0000269|PubMed:16596670,
FT                                ECO:0000269|PubMed:16791849}.
FT                                /FTId=VAR_029482.
FT   VARIANT     266    266       D -> Y (in LDS1).
FT                                {ECO:0000269|PubMed:22113417}.
FT                                /FTId=VAR_066720.
FT   VARIANT     267    267       N -> H (in a patient with Marfan
FT                                syndrome). {ECO:0000269|PubMed:16791849}.
FT                                /FTId=VAR_029483.
FT   VARIANT     291    291       Y -> C (in dbSNP:rs35974499).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041413.
FT   VARIANT     318    318       M -> R (in LDS1; dbSNP:rs121918710).
FT                                {ECO:0000269|PubMed:15731757}.
FT                                /FTId=VAR_022345.
FT   VARIANT     351    351       D -> G (in LDS1).
FT                                {ECO:0000269|PubMed:19883511}.
FT                                /FTId=VAR_066721.
FT   VARIANT     375    375       T -> R (in LDS1).
FT                                {ECO:0000269|PubMed:22113417}.
FT                                /FTId=VAR_066722.
FT   VARIANT     400    400       D -> G (in LDS1; dbSNP:rs121918711).
FT                                {ECO:0000269|PubMed:15731757}.
FT                                /FTId=VAR_022346.
FT   VARIANT     487    487       R -> P (in LDS1; dbSNP:rs113605875).
FT                                {ECO:0000269|PubMed:15731757,
FT                                ECO:0000269|PubMed:16928994}.
FT                                /FTId=VAR_022347.
FT   VARIANT     487    487       R -> Q (in LDS1; dbSNP:rs113605875).
FT                                {ECO:0000269|PubMed:16791849,
FT                                ECO:0000269|PubMed:16928994,
FT                                ECO:0000269|PubMed:22113417}.
FT                                /FTId=VAR_029484.
FT   VARIANT     487    487       R -> W (in LDS1; dbSNP:rs111426349).
FT                                {ECO:0000269|PubMed:16928994}.
FT                                /FTId=VAR_029485.
FT   MUTAGEN     185    186       TT->VV: Loss of phosphorylation on
FT                                threonine residues. Loss of threonine
FT                                phosphorylation, reduced phosphorylation
FT                                on serine residues and loss of response
FT                                to TGF-beta; when associated with A-187;
FT                                A-189 and A-191.
FT                                {ECO:0000269|PubMed:7774578}.
FT   MUTAGEN     187    187       S->A: Loss of threonine phosphorylation,
FT                                reduced phosphorylation on serine
FT                                residues and loss of response to TGF-
FT                                beta; when associated with 185-VV-186; A-
FT                                189 and A-191.
FT                                {ECO:0000269|PubMed:7774578}.
FT   MUTAGEN     189    189       S->A: Loss of threonine phosphorylation,
FT                                reduced phosphorylation on serine
FT                                residues and loss of response to TGF-
FT                                beta; when associated with 185-VV-186; A-
FT                                187 and A-191.
FT                                {ECO:0000269|PubMed:7774578}.
FT   MUTAGEN     191    191       S->A: Loss of threonine phosphorylation,
FT                                reduced phosphorylation on serine
FT                                residues and loss of response to TGF-
FT                                beta; when associated with 185-VV-186; A-
FT                                187 and A-189.
FT                                {ECO:0000269|PubMed:7774578}.
FT   MUTAGEN     193    193       L->G: Loss of interaction with FKBP1A.
FT                                {ECO:0000269|PubMed:9233797}.
FT   MUTAGEN     194    194       P->K: Loss of interaction with FKBP1A.
FT                                {ECO:0000269|PubMed:9233797}.
FT   MUTAGEN     200    200       T->D: Loss of response to TGF-beta.
FT                                {ECO:0000269|PubMed:7774578}.
FT   MUTAGEN     200    200       T->V: Loss of phosphorylation. Loss of
FT                                response to TGF-beta.
FT                                {ECO:0000269|PubMed:7774578}.
FT   MUTAGEN     204    204       T->D: Constitutive activation.
FT                                {ECO:0000269|PubMed:7774578}.
FT   MUTAGEN     204    204       T->V: Reduced phosphorylation. Reduced
FT                                response to TGF-beta.
FT                                {ECO:0000269|PubMed:7774578}.
FT   STRAND       35     37       {ECO:0000244|PDB:3KFD}.
FT   TURN         42     46       {ECO:0000244|PDB:3KFD}.
FT   STRAND       51     57       {ECO:0000244|PDB:3KFD}.
FT   STRAND       61     63       {ECO:0000244|PDB:2PJY}.
FT   STRAND       69     72       {ECO:0000244|PDB:3KFD}.
FT   TURN         74     76       {ECO:0000244|PDB:3KFD}.
FT   STRAND       77     82       {ECO:0000244|PDB:2PJY}.
FT   TURN         84     86       {ECO:0000244|PDB:3KFD}.
FT   HELIX        89     92       {ECO:0000244|PDB:2PJY}.
FT   STRAND       94    101       {ECO:0000244|PDB:2PJY}.
FT   STRAND      102    105       {ECO:0000244|PDB:3KFD}.
FT   HELIX       107    109       {ECO:0000244|PDB:2L5S}.
FT   HELIX       177    183       {ECO:0000244|PDB:1B6C}.
FT   STRAND      187    190       {ECO:0000244|PDB:3KCF}.
FT   STRAND      191    193       {ECO:0000244|PDB:1B6C}.
FT   HELIX       202    204       {ECO:0000244|PDB:5E8S}.
FT   STRAND      205    213       {ECO:0000244|PDB:5E8S}.
FT   STRAND      215    224       {ECO:0000244|PDB:5E8S}.
FT   STRAND      227    234       {ECO:0000244|PDB:5E8S}.
FT   HELIX       236    238       {ECO:0000244|PDB:5E8S}.
FT   HELIX       239    249       {ECO:0000244|PDB:5E8S}.
FT   STRAND      251    253       {ECO:0000244|PDB:3KCF}.
FT   STRAND      262    269       {ECO:0000244|PDB:5E8S}.
FT   STRAND      271    281       {ECO:0000244|PDB:5E8S}.
FT   HELIX       288    294       {ECO:0000244|PDB:5E8S}.
FT   HELIX       299    317       {ECO:0000244|PDB:5E8S}.
FT   STRAND      322    324       {ECO:0000244|PDB:5E8X}.
FT   STRAND      328    330       {ECO:0000244|PDB:5E8Z}.
FT   HELIX       336    338       {ECO:0000244|PDB:5E8S}.
FT   STRAND      339    341       {ECO:0000244|PDB:5E8S}.
FT   STRAND      347    349       {ECO:0000244|PDB:5E8S}.
FT   HELIX       352    354       {ECO:0000244|PDB:5E8S}.
FT   STRAND      356    359       {ECO:0000244|PDB:5E8S}.
FT   TURN        360    363       {ECO:0000244|PDB:5E8S}.
FT   STRAND      364    367       {ECO:0000244|PDB:5E8S}.
FT   STRAND      368    371       {ECO:0000244|PDB:5E8X}.
FT   HELIX       376    378       {ECO:0000244|PDB:5E8S}.
FT   HELIX       381    384       {ECO:0000244|PDB:5E8S}.
FT   HELIX       393    413       {ECO:0000244|PDB:5E8S}.
FT   STRAND      417    419       {ECO:0000244|PDB:3KCF}.
FT   TURN        427    431       {ECO:0000244|PDB:5E8S}.
FT   HELIX       438    445       {ECO:0000244|PDB:5E8S}.
FT   HELIX       456    460       {ECO:0000244|PDB:5E8S}.
FT   HELIX       462    474       {ECO:0000244|PDB:5E8S}.
FT   HELIX       479    481       {ECO:0000244|PDB:5E8S}.
FT   HELIX       485    497       {ECO:0000244|PDB:5E8S}.
SQ   SEQUENCE   503 AA;  55960 MW;  179F11404725DDCB CRC64;
     MEAAVAAPRP RLLLLVLAAA AAAAAALLPG ATALQCFCHL CTKDNFTCVT DGLCFVSVTE
     TTDKVIHNSM CIAEIDLIPR DRPFVCAPSS KTGSVTTTYC CNQDHCNKIE LPTTVKSSPG
     LGPVELAAVI AGPVCFVCIS LMLMVYICHN RTVIHHRVPN EEDPSLDRPF ISEGTTLKDL
     IYDMTTSGSG SGLPLLVQRT IARTIVLQES IGKGRFGEVW RGKWRGEEVA VKIFSSREER
     SWFREAEIYQ TVMLRHENIL GFIAADNKDN GTWTQLWLVS DYHEHGSLFD YLNRYTVTVE
     GMIKLALSTA SGLAHLHMEI VGTQGKPAIA HRDLKSKNIL VKKNGTCCIA DLGLAVRHDS
     ATDTIDIAPN HRVGTKRYMA PEVLDDSINM KHFESFKRAD IYAMGLVFWE IARRCSIGGI
     HEDYQLPYYD LVPSDPSVEE MRKVVCEQKL RPNIPNRWQS CEALRVMAKI MRECWYANGA
     ARLTALRIKK TLSQLSQQEG IKM
//
